LM11A 31

Drug Profile

LM11A 31

Alternative Names: LM11A-31; LM11A-31-BHS

Latest Information Update: 29 Jul 2016

Price : $50

At a glance

  • Originator PharmatrophiX
  • Class Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 11 Jun 2016 Phase-II clinical trials in Alzheimer's disease (In adults, In the elderly) in Austria (PO) (EudraCT2015-005263-16)
  • 19 May 2016 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top